

WD

24. (New) The purified immunological complex of claim 15, wherein the peptide has the sequence of HIV-1 ORF-Q.

NO

25. (New) The purified immunological complex of claim 15, wherein the peptide has the sequence of HIV-1 ORF-R.

26. (New) The purified immunological complex of claim 15, wherein the peptide has the sequence of HIV-1 ORF-1.

27. (New) The purified immunological complex of claim 15, wherein the peptide has the sequence of HIV-1 ORF-4.

28. (New) The purified monoclonal antibody of claim 17, wherein the peptide has the sequence of HIV-1 ORF-Q.

29. (New) The purified monoclonal antibody of claim 17, wherein the peptide has the sequence of HIV-1 ORF-R.

30. (New) The purified monoclonal antibody of claim 17, wherein the peptide has the sequence of HIV-1 ORF-1.

HI

31. (New) The purified monoclonal antibody of claim 17, wherein the peptide has the sequence of HIV-1 ORF-4.

WD

32. (New) The purified immunological complex of claim 19, wherein the peptide has the sequence of HIV-1 ORF-Q.

NO

33. (New) The purified immunological complex of claim 19, wherein the peptide has the sequence of HIV-1 ORF-R.

34. (New) The purified immunological complex of claim 19, wherein the peptide has the sequence of HIV-1 ORF-1.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com